Physician profile
Frederick Carroll
NPI 1962431957
$14,175.53
in general payments reported to CMS, 2019-2025
76 companies · $785 in 2025
The $785 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,857 · 2020: $1,386 · 2021: $1,842 · 2022: $2,249 · 2023: $3,244 · 2024: $2,811 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,841.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,476.02 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,452.75 | 2019-2025 | Linzess, Ubrelvy, Viberzi |
| Astrazeneca Pharmaceuticals LP | $1,012.11 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $915.71 | 2019-2025 | |
| Glaxosmithkline, LLC. | $865.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $666.18 | 2019-2025 | Xarelto, Spravato |
| Lilly USA, LLC | $530.86 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $521.09 | 2019-2024 | Trulance, Xifaxan, Cycloset |
| Amgen INC. | $475.83 | 2019-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $444.73 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $443.05 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.64 | 2019-2024 | Jardiance, Stiolto Respimat |
| Otsuka America Pharmaceutical, INC. | $331.16 | 2019-2024 | Rexulti |
| Exact Sciences Corporation | $329.37 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $326.03 | 2019-2025 |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.